A study that prompted hope for a COVID-19 treatment in the early days of the pandemic has now been formally retracted by the scientific journal that published it. Hydroxychloroquine, an antimalarial drug also approved for use in some autoimmune diseases,

The FDA in March 2020 issued an emergency use authorization (EUA), allowing doctors to treat COVID patients in the hospital with hydroxychloroquine. However, the temporary authorization was revoked three months later after more robust studies failed to find a benefit that outweighed potential risks.